EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study

Tao Huang, Zhimin Fan, Yongsheng Wang, Xi Yan, Hongjian Yang, Shu Wang, Da Pang, Huiping Li, Haibo Wang, Cuizhi Geng, Liang Huang, Yaqing Sun und 5 weitere

International Journal of Clinical Oncology · 2026-07 · 31 (7) · 1189-1200

DOI: 10.1007/s10147-025-02935-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 07.05.2026. Verfasst von Tao Huang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Trastuzumab, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: F. Hoffmann-La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) demonstrated non-inferior cycle 7 pertuzumab and trastuzumab serum trough concentrations (C trough ), and similar total pathological complete response (tpCR) rates and safety, to intravenous pertuzumab plus trastuzumab (P + H IV) in HER2-positive early breast cancer (eBC). In the FDChina study (NCT04024462), we assessed neoadjuvant–adjuvant PH FDC SC vs. P + H IV in Chinese patients with HER2-positive eBC.

Methods

Patients received four doxorubicin (60 mg/m 2 ) plus cyclophosphamide (600 mg/m 2 ), then four docetaxel (75–100 mg/m 2 ) cycles, every 3 weeks. Patients were randomized 1:1 to PH FDC SC (loading: 1200 mg pertuzumab/600 mg trastuzumab; maintenance: 600 mg/600 mg) or P + H IV (loading: 840 mg/8 mg/kg; maintenance: 420 mg/6 mg/kg) alongside docetaxel before surgery. Patients then continued HER2-targeted therapy for 14 cycles. Co-primary non-inferiority endpoints: cycle 7 pertuzumab and trastuzumab C trough . Secondary endpoints: tpCR, long-term efficacy, safety.

Results

The lower bounds of the 90% confidence intervals of pertuzumab and trastuzumab cycle 7 geometric mean ratios (0.99 and 1.44, respectively) exceeded the pre-specified non-inferiority margin (0.8). tpCR rates were 55.6% for PH FDC SC vs. 56.4% for P + H IV. Grade ≥ 3 adverse events occurred in 72% vs. 69% of patients.

Conclusion

The study met the co-primary endpoints of non-inferiority of cycle 7 serum C trough for pertuzumab and trastuzumab for PH FDC SC vs. P + H IV. tpCR rates and safety were comparable between arms. PH FDC SC may be a viable treatment option for Chinese patients with HER2-positive eBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedTrastuzumabBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedInjections, SubcutaneousAdultDocetaxelAgedCyclophosphamideNeoadjuvant TherapyDoxorubicinPathologic Complete ResponseEast Asian People

Stichwörter der Autor:innen

Chinese patientsFixed-dose combinationHER2-positive early breast cancerPertuzumabSubcutaneousTrastuzumab

Substanzen

pertuzumabAntibodies, Monoclonal, HumanizedTrastuzumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanDocetaxelCyclophosphamideDoxorubicin

Autor:innen und Institutionen

  • Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
  • Department of Breast Surgery, Jilin University, Changchun, 130021, China.
  • Breast Cancer Center, Shandong Cancer Hospital, Jinan, 250117, China.
  • Medical Oncology, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Breast Surgery, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
  • Breast Center, Peking University People's Hospital, Beijing, 100044, China.

Förderung

  • F. Hoffmann-La Roche

Zitieren

APA

Huang, T., Fan, Z., Wang, Y., Yan, X., Yang, H., Wang, S., Pang, D., Li, H., Wang, H., Geng, C., Huang, L., Sun, Y., Wang, B., Sun, G., Siddiqui, A., Restuccia, E., & Shao, Z. (2026). The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study. International Journal of Clinical Oncology, 31(7), 1189-1200. https://doi.org/10.1007/s10147-025-02935-7

Vancouver

Huang T, Fan Z, Wang Y, Yan X, Yang H, Wang S, et al. The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study. International Journal of Clinical Oncology. 2026;31(7):1189-1200. doi:10.1007/s10147-025-02935-7

BibTeX
@article{Huang2026,
  author = {Huang, Tao and Fan, Zhimin and Wang, Yongsheng and Yan, Xi and Yang, Hongjian and Wang, Shu and Pang, Da and Li, Huiping and Wang, Haibo and Geng, Cuizhi and Huang, Liang and Sun, Yaqing and Wang, Bei and Sun, Guofang and Siddiqui, Asna and Restuccia, Eleonora and Shao, Zhimin},
  title = {The fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in Chinese patients with HER2-positive early breast cancer: primary analysis of the phase III, randomized FDChina study},
  journal = {International Journal of Clinical Oncology},
  year = {2026},
  volume = {31},
  number = {7},
  pages = {1189--1200},
  doi = {10.1007/s10147-025-02935-7}
}
Kostenlos starten →